PL377479A1 - Kontrolowane uwalnianie substancji czynnej do środowiska o wysokiej zawartości tłuszczu - Google Patents

Kontrolowane uwalnianie substancji czynnej do środowiska o wysokiej zawartości tłuszczu

Info

Publication number
PL377479A1
PL377479A1 PL377479A PL37747903A PL377479A1 PL 377479 A1 PL377479 A1 PL 377479A1 PL 377479 A PL377479 A PL 377479A PL 37747903 A PL37747903 A PL 37747903A PL 377479 A1 PL377479 A1 PL 377479A1
Authority
PL
Poland
Prior art keywords
release
controlled
active substance
high fat
fat environment
Prior art date
Application number
PL377479A
Other languages
English (en)
Polish (pl)
Inventor
Mark Brian Chidlaw
Dwayne Thomas Friesen
Scott Max Herbig
James Alan Schriver Nightingale
Cynthia Ann Oksanen
James Blair West
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of PL377479A1 publication Critical patent/PL377479A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL377479A 2002-12-11 2003-11-28 Kontrolowane uwalnianie substancji czynnej do środowiska o wysokiej zawartości tłuszczu PL377479A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43286002P 2002-12-11 2002-12-11

Publications (1)

Publication Number Publication Date
PL377479A1 true PL377479A1 (pl) 2006-02-06

Family

ID=32508002

Family Applications (1)

Application Number Title Priority Date Filing Date
PL377479A PL377479A1 (pl) 2002-12-11 2003-11-28 Kontrolowane uwalnianie substancji czynnej do środowiska o wysokiej zawartości tłuszczu

Country Status (18)

Country Link
US (1) US20040121015A1 (enExample)
EP (1) EP1572163A1 (enExample)
JP (1) JP2006510655A (enExample)
KR (1) KR20050088311A (enExample)
CN (1) CN1726012A (enExample)
AR (1) AR042340A1 (enExample)
AU (1) AU2003283688A1 (enExample)
BR (1) BR0317275A (enExample)
CA (1) CA2508722A1 (enExample)
CO (1) CO5570656A2 (enExample)
MX (1) MXPA05005812A (enExample)
NO (1) NO20053068L (enExample)
NZ (1) NZ539915A (enExample)
PL (1) PL377479A1 (enExample)
RU (1) RU2308263C2 (enExample)
TW (1) TWI257302B (enExample)
WO (1) WO2004052343A1 (enExample)
ZA (1) ZA200503812B (enExample)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030086972A1 (en) * 2000-08-09 2003-05-08 Appel Leah E. Hydrogel-driven drug dosage form
FR2830447B1 (fr) * 2001-10-09 2004-04-16 Flamel Tech Sa Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
CN100553625C (zh) 2002-04-09 2009-10-28 弗拉梅技术公司 活性成分微囊的口服混悬液
MXPA04009979A (es) * 2002-04-09 2004-12-13 Flamel Tech Sa Formulacion farmaceutica oral bajo forma de suspension acuosa de microcapsulas que permiten la liberacion modificada de amoxicilina.
US20090088465A1 (en) * 2004-12-02 2009-04-02 Stephen Craig Dyar Pharmaceutical Compositions of Amorphous Atorvastatin and Process for Preparing Same
CA2596240A1 (en) * 2005-01-28 2006-08-03 Pfizer Products Inc. Fast-disintegrating microporous binder and process for making it
ES2403069T3 (es) * 2005-02-22 2013-05-13 Sun Pharma Advanced Research Company Ltd Composición oral de liberación controlada que contiene levetiracetam
PL1874282T3 (pl) * 2005-04-06 2011-04-29 Adamas Pharmaceuticals Inc Sposoby i kompozycje do leczenia zaburzeń OUN
CA2789097C (en) 2005-04-28 2017-02-21 Proteus Digital Health, Inc. Pharma-informatics system
US8730031B2 (en) 2005-04-28 2014-05-20 Proteus Digital Health, Inc. Communication system using an implantable device
US9198608B2 (en) 2005-04-28 2015-12-01 Proteus Digital Health, Inc. Communication system incorporated in a container
US8802183B2 (en) 2005-04-28 2014-08-12 Proteus Digital Health, Inc. Communication system with enhanced partial power source and method of manufacturing same
US8912908B2 (en) 2005-04-28 2014-12-16 Proteus Digital Health, Inc. Communication system with remote activation
US8836513B2 (en) 2006-04-28 2014-09-16 Proteus Digital Health, Inc. Communication system incorporated in an ingestible product
FR2886150B1 (fr) * 2005-05-24 2007-08-24 Flamel Technologies Sa Forme pharmaceutique orale a base d'au moins un principe actif dont la solubilite varie en fonction des conditions de ph gastrique
JP5714210B2 (ja) 2005-09-01 2015-05-07 プロテウス デジタル ヘルス， インコーポレイテッド 移植可能なワイヤ無し通信システム
CN101496042A (zh) 2006-05-02 2009-07-29 普罗秋斯生物医学公司 患者定制的治疗方案
ATE535057T1 (de) 2006-10-17 2011-12-15 Proteus Biomedical Inc Niederspannungsoszillator für medizinische einrichtungen
EP2083680B1 (en) 2006-10-25 2016-08-10 Proteus Digital Health, Inc. Controlled activation ingestible identifier
WO2008063626A2 (en) 2006-11-20 2008-05-29 Proteus Biomedical, Inc. Active signal processing personal health signal receivers
AU2008210291B2 (en) 2007-02-01 2013-10-03 Otsuka Pharmaceutical Co., Ltd. Ingestible event marker systems
CN101636865B (zh) * 2007-02-14 2012-09-05 普罗秋斯生物医学公司 具有高表面积电极的体内电源
US9270025B2 (en) 2007-03-09 2016-02-23 Proteus Digital Health, Inc. In-body device having deployable antenna
EP2124725A1 (en) 2007-03-09 2009-12-02 Proteus Biomedical, Inc. In-body device having a multi-directional transmitter
US20080299188A1 (en) * 2007-05-14 2008-12-04 Pfizer Inc. Controlled release dosage forms combining immediate release and sustainted release of low-solubility drug
US8115618B2 (en) 2007-05-24 2012-02-14 Proteus Biomedical, Inc. RFID antenna for in-body device
US8961412B2 (en) 2007-09-25 2015-02-24 Proteus Digital Health, Inc. In-body device with virtual dipole signal amplification
US8707964B2 (en) * 2007-10-31 2014-04-29 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
US8789536B2 (en) 2007-10-17 2014-07-29 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
US20090105561A1 (en) * 2007-10-17 2009-04-23 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Medical or veterinary digestive tract utilization systems and methods
US8808276B2 (en) * 2007-10-23 2014-08-19 The Invention Science Fund I, Llc Adaptive dispensation in a digestive tract
US8808271B2 (en) * 2007-10-31 2014-08-19 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
US20090163894A1 (en) * 2007-10-31 2009-06-25 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Medical or veterinary digestive tract utilization systems and methods
KR100920106B1 (ko) * 2007-11-14 2009-10-01 경북대학교 산학협력단 구연산 실데나필을 경피적으로 전달하기 위한 조절 약물전달체 및 이를 포함하는 경피 패치
EP2215726B1 (en) 2007-11-27 2018-01-10 Proteus Digital Health, Inc. Transbody communication systems employing communication channels
EP3235491B1 (en) 2008-03-05 2020-11-04 Proteus Digital Health, Inc. Multi-mode communication ingestible event markers and systems
AU2009268827B2 (en) 2008-07-08 2013-10-24 Proteus Digital Health, Inc. Ingestible event marker data framework
EP2313003B1 (en) 2008-08-13 2016-08-03 Proteus Digital Health, Inc. Ingestible circuitry
MX385591B (es) 2008-08-15 2025-03-18 Ironwood Pharmaceuticals Inc Formulaciones que contienen linaclotida para administracion oral.
AU2009313879B2 (en) * 2008-11-13 2011-10-20 Proteus Digital Health, Inc. Ingestible therapy activator system and method
WO2010068818A2 (en) * 2008-12-11 2010-06-17 Proteus Biomedical, Inc. Evaluation of gastrointestinal function using portable electroviscerography systems and methods of using the same
US9659423B2 (en) 2008-12-15 2017-05-23 Proteus Digital Health, Inc. Personal authentication apparatus system and method
TWI424832B (zh) 2008-12-15 2014-02-01 Proteus Digital Health Inc 與身體有關的接收器及其方法
US9439566B2 (en) 2008-12-15 2016-09-13 Proteus Digital Health, Inc. Re-wearable wireless device
JP2012514799A (ja) 2009-01-06 2012-06-28 プロテウス バイオメディカル インコーポレイテッド 摂取に関連するバイオフィードバックおよび個別薬物療法の方法およびシステム
TWI602561B (zh) 2009-01-06 2017-10-21 波提亞斯數位康健公司 醫藥劑量傳送系統
US8540664B2 (en) 2009-03-25 2013-09-24 Proteus Digital Health, Inc. Probablistic pharmacokinetic and pharmacodynamic modeling
EP2424427B1 (en) 2009-04-28 2021-06-16 Otsuka Pharmaceutical Co., Ltd. Highly reliable ingestible event markers
US9149423B2 (en) 2009-05-12 2015-10-06 Proteus Digital Health, Inc. Ingestible event markers comprising an ingestible component
MX2012001660A (es) 2009-08-06 2012-03-26 Ironwood Pharmaceuticals Inc Formulaciones que contienen linaclotida para adminstracion oral.
WO2011022732A2 (en) 2009-08-21 2011-02-24 Proteus Biomedical, Inc. Apparatus and method for measuring biochemical parameters
TWI517050B (zh) 2009-11-04 2016-01-11 普羅托斯數位健康公司 供應鏈管理之系統
UA109424C2 (uk) 2009-12-02 2015-08-25 Фармацевтичний продукт, фармацевтична таблетка з електронним маркером і спосіб виготовлення фармацевтичної таблетки
KR101193495B1 (ko) * 2010-02-01 2012-10-23 한미사이언스 주식회사 슈도에페드린 및 레보세티리진을 포함하는 경구용 복합 조성물
WO2011094606A2 (en) 2010-02-01 2011-08-04 Proteus Biomedical, Inc. Data gathering system
WO2011103311A2 (en) 2010-02-17 2011-08-25 Ironwood Pharmaceuticals, Inc Treatments for gastrointestinal disorders
SG10201502720VA (en) 2010-04-07 2015-05-28 Proteus Digital Health Inc Miniature ingestible device
TWI557672B (zh) 2010-05-19 2016-11-11 波提亞斯數位康健公司 用於從製造商跟蹤藥物直到患者之電腦系統及電腦實施之方法、用於確認將藥物給予患者的設備及方法、患者介面裝置
RS59978B1 (sr) 2010-08-11 2020-03-31 Ironwood Pharmaceuticals Inc Stabilne formulacije linaklotida
US9107806B2 (en) 2010-11-22 2015-08-18 Proteus Digital Health, Inc. Ingestible device with pharmaceutical product
WO2012125425A2 (en) 2011-03-11 2012-09-20 Proteus Biomedical, Inc. Wearable personal body associated device with various physical configurations
WO2015112603A1 (en) 2014-01-21 2015-07-30 Proteus Digital Health, Inc. Masticable ingestible product and communication system therefor
US9756874B2 (en) 2011-07-11 2017-09-12 Proteus Digital Health, Inc. Masticable ingestible product and communication system therefor
UA118745C2 (uk) 2011-07-21 2019-03-11 Протеус Діджитал Хелс, Інк. Пристрій, система та спосіб мобільного зв'язку
EP2776055B1 (en) 2011-08-17 2016-12-14 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
US9235683B2 (en) 2011-11-09 2016-01-12 Proteus Digital Health, Inc. Apparatus, system, and method for managing adherence to a regimen
CN104487347B (zh) 2012-07-23 2017-09-01 普罗秋斯数字健康公司 用于制造包括电子器件的片剂的方法和系统
AU2013331417B2 (en) 2012-10-18 2016-06-02 Proteus Digital Health, Inc. Apparatus, system, and method to adaptively optimize power dissipation and broadcast power in a power source for a communication device
WO2014120669A1 (en) 2013-01-29 2014-08-07 Proteus Digital Health, Inc. Highly-swellable polymeric films and compositions comprising the same
WO2014151929A1 (en) 2013-03-15 2014-09-25 Proteus Digital Health, Inc. Personal authentication apparatus system and method
JP5941240B2 (ja) 2013-03-15 2016-06-29 プロテウス デジタル ヘルス， インコーポレイテッド 金属検出器装置、システム、および方法
JP6511439B2 (ja) 2013-06-04 2019-05-15 プロテウス デジタル ヘルス， インコーポレイテッド データ収集および転帰の査定のためのシステム、装置、および方法
US9796576B2 (en) 2013-08-30 2017-10-24 Proteus Digital Health, Inc. Container with electronically controlled interlock
CN105556912B (zh) 2013-09-20 2019-05-31 普罗秋斯数字健康公司 使用切片和扭曲在存在噪声的情况下接收和解码信号的方法、器件和系统
WO2015044722A1 (en) 2013-09-24 2015-04-02 Proteus Digital Health, Inc. Method and apparatus for use with received electromagnetic signal at a frequency not known exactly in advance
US10084880B2 (en) 2013-11-04 2018-09-25 Proteus Digital Health, Inc. Social media networking based on physiologic information
US11051543B2 (en) 2015-07-21 2021-07-06 Otsuka Pharmaceutical Co. Ltd. Alginate on adhesive bilayer laminate film
SG11201900511VA (en) 2016-07-22 2019-02-27 Proteus Digital Health Inc Electromagnetic sensing and detection of ingestible event markers
WO2018081337A1 (en) 2016-10-26 2018-05-03 Proteus Digital Health, Inc. Methods for manufacturing capsules with ingestible event markers
CN111214456A (zh) * 2020-03-10 2020-06-02 浙江普利药业有限公司 伏立康唑干混悬剂及其制备方法
EP4188339A1 (en) * 2020-07-30 2023-06-07 Faes Farma, S.A. Decongestant drug delivery system
CN112198274B (zh) * 2020-11-02 2022-04-05 北京市理化分析测试中心 一种检测氨酚伪麻片中盐酸伪麻黄碱的方法
CN113514579A (zh) * 2021-06-23 2021-10-19 远大生命科学(武汉)有限公司 一种依托咪酯乳状注射液体外释放曲线的测定方法
CN115647000B (zh) * 2022-10-26 2025-06-27 华能阜新风力发电有限责任公司 一种基于低温热解的风电叶片回收方法及其应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4014334A (en) * 1976-02-02 1977-03-29 Alza Corporation Laminated osmotic system for dispensing beneficial agent
US4203439A (en) * 1976-11-22 1980-05-20 Alza Corporation Osmotic system with volume amplifier for increasing amount of agent delivered therefrom
US4285987A (en) * 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US5366738A (en) * 1982-07-29 1994-11-22 Merck & Co., Inc. Controlled release drug dispersion delivery device
US4765989A (en) * 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4783337A (en) * 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US5364620A (en) * 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US4968507A (en) * 1984-06-20 1990-11-06 Merck & Co., Inc. Controlled porosity osmotic pump
US4851228A (en) * 1984-06-20 1989-07-25 Merck & Co., Inc. Multiparticulate controlled porosity osmotic
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4801461A (en) * 1987-01-28 1989-01-31 Alza Corporation Pseudoephedrine dosage form
IE60383B1 (en) * 1988-05-27 1994-07-13 Elan Corp Plc Controlled release pharmaceutical formulation
US5612059A (en) * 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
GB8926639D0 (en) * 1989-11-24 1990-01-17 Agricultural & Food Res Delayed release formulations
IE66933B1 (en) * 1990-01-15 1996-02-07 Elan Corp Plc Controlled absorption naproxen formulation for once-daily administration
US5324280A (en) * 1990-04-02 1994-06-28 Alza Corporation Osmotic dosage system for delivering a formulation comprising liquid carrier and drug
AU3941493A (en) * 1992-03-30 1993-11-08 Alza Corporation Viscous suspensions of controlled-release drug particles
US5718700A (en) * 1994-09-20 1998-02-17 Alza Corporation Exit means in dosage form
US5567441A (en) * 1995-03-24 1996-10-22 Andrx Pharmaceuticals Inc. Diltiazem controlled release formulation
US5736159A (en) * 1995-04-28 1998-04-07 Andrx Pharmaceuticals, Inc. Controlled release formulation for water insoluble drugs in which a passageway is formed in situ
ATE250929T1 (de) * 1997-05-30 2003-10-15 Osmotica Corp Mehrlagige osmosevorrichtung
US6245357B1 (en) * 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
US6136835A (en) * 1999-05-17 2000-10-24 The Procter & Gamble Company Methods of treatment for viral infections
US6352721B1 (en) * 2000-01-14 2002-03-05 Osmotica Corp. Combined diffusion/osmotic pumping drug delivery system

Also Published As

Publication number Publication date
WO2004052343A1 (en) 2004-06-24
TWI257302B (en) 2006-07-01
CO5570656A2 (es) 2005-10-31
CA2508722A1 (en) 2004-06-24
NZ539915A (en) 2007-09-28
EP1572163A1 (en) 2005-09-14
ZA200503812B (en) 2006-07-26
JP2006510655A (ja) 2006-03-30
AU2003283688A1 (en) 2004-06-30
RU2308263C2 (ru) 2007-10-20
US20040121015A1 (en) 2004-06-24
NO20053068L (no) 2005-09-07
MXPA05005812A (es) 2005-08-16
NO20053068D0 (no) 2005-06-22
AR042340A1 (es) 2005-06-15
TW200425888A (en) 2004-12-01
CN1726012A (zh) 2006-01-25
KR20050088311A (ko) 2005-09-05
RU2005118101A (ru) 2006-01-20
BR0317275A (pt) 2005-11-08

Similar Documents

Publication Publication Date Title
PL377479A1 (pl) Kontrolowane uwalnianie substancji czynnej do środowiska o wysokiej zawartości tłuszczu
PL374390A1 (en) Fungicidal active substance combinations
AU2003252299A8 (en) Novel physiologically active substance
SI1608362T1 (sl) Stabiliziran farmacevtski izdelek z amorfno aktivno učinkovino
PL372084A1 (en) 8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient
AU2003267255A8 (en) Methods and devices for active bioassay
PT1362582E (pt) Forma de dosagem sólida revestida
AU2003232851A1 (en) Fungicidal combinations of active substances
NO20042367L (no) Mikronisert filmdannende pulver omfattende et aktivt stoff
IL164699A0 (en) Diketohydrazine derivative compounds and drugs containing the compounds as the active ingredient
AU2003238179A8 (en) Herbicidally active heterocyclylalkynes
EP1450860A4 (en) ANIMAL FEED COMPRISING ACTIVE INGREDIENTS AND METHODS OF USE THEREOF
EP1590144A4 (en) PROCESS FOR THE PREPARATION OF BIOLOGICALLY ACTIVE FORMULATIONS
GB0212143D0 (en) Processor Monitor
GB0205347D0 (en) Biologically active complex
AU2003260721A1 (en) Fish enclosure
AUPS015802A0 (en) Fumigant formulation
HU0303383D0 (en) Pellets containing active ingredient
GB0219897D0 (en) Pharmaceutically active compounds
ZA200508282B (en) Method of preparing a formulation containing a microdosed active principle
AU2003300696A8 (en) Chemoenzymatically hydrolysable biologically active compounds
GB0219893D0 (en) Pharmaceutically active compounds
TW527872U (en) Structure improvement of shoes for farming use
SI1517609T1 (sl) Fungicidne kombinacije učinkovin
TW555097U (en) Improved structure of wireless mouse housing

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)